A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Ertapenem in Intraabdominal Infections, sponsored by Bayer. Completed at 39 sites in 16 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-03-20.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to \<18 years old. Approximately 450 pediatric subjects with a complicated intra-abdominal infection will be enrolled in the study and treated with either moxifloxacin intravenously and orally if switched to oral therapy or ertapenem (intravenously) and, if switched to oral therapy, amoxicillin/clavulanate.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
This study's enrollment of 458 is above the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Browse Intraabdominal Infections studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects may be enrolled upon a surgically (laparotomy, laparoscopy, or percutaneous drainage) confirmed cIAI revealing at least one of the following:
Subjects may be enrolled on the basis of a suspected cIAI, which must be supported with radiological evidence (ultrasound, abdominal plain films, computed tomography [CT], magnetic resonance imaging [MRI]) of gastrointestinal perforation or localized collections of potentially infected material and at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride \[NaCl solution\]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
Drug: Moxifloxacin (Avelox, BAY12-8039) · Drug: Ertapenem placebo · Drug: Amoxicillin/Clavulanate placebo
Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
Drug: Ertapenem · Drug: Amoxicillin/Clavulanate · Drug: Moxifloxacin placebo
For subjects 12 to less than (\<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to \< 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to \< 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
For subjects 13 to \<18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to \< 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
Drug pages: Amoxicillin · Clavulanic Acid
Subjects 2 years to \< 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
Number of Subjects With Adverse Events
An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Number of Subjects With Clinical Cardiac Adverse Events
Time frame: Clinical cardiac event related to QT interval were recorded from treatment start until day 3 of treatment. All other clinical cardiac events were recorded from treatment start to test of cure visit, up to day 56.
Number of Subjects With Musculoskeletal Adverse Events
Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term
Musculoskeletal adverse events were classified as following SOCs (preferred terms): "injury, poisoning and procedural complications" (forearm fracture, joint injury, ligament sprain, muscle strain) "musculoskeletal and connective tissue disorders" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.
Time frame: All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.
Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
"N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
The RR interval refers to the respective time interval in the Electrocardiogram. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3
The QRS interval represents the time it takes for ventricular depolarization to occur. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3
QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
Time frame: Baseline (Pre-dose), Day 1, Day 3
Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3
A significant QTc prolongation was considered when the QTc value was more than (\>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
Time frame: Baseline (Pre-dose), Day 1, Day 3
Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3
A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
Time frame: Baseline (Pre-dose), Day 1, Day 3
Clinical Response at Test-of-Cure (TOC) Visit
Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.
Time frame: 28 to 42 days
Bacteriological Response at Test-of-Cure (TOC) Visit
Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate. 'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; índeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.
Time frame: 28 to 42 days
Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)
Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported
Time frame: 28 to 42 days
Clinical Response at a 'During Therapy' Visit
Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy. 'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.
Time frame: Day 3 to Day 5
Bacteriological Response at a 'During Therapy' Visit
Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported
Time frame: Day 3 to Day 5
Clinical Response at the End-of-Treatment (EOT) Visit
Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.
Time frame: Day 5 to Day 14
Bacteriological Response at the End of Treatment (EOT) Visit
Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.
Time frame: Day 5 to Day 14
The study was conducted at multicenter between 21 July 2010 (first subject first visit) to 21 January 2015 (last subject last visit).
| Milestone | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Started | 305 | 153 |
| Treated | 301 | 150 |
| Completed | 287 | 149 |
| Not completed | 18 | 4 |
| Withdrew: Technical problems | 0 | 1 |
| Withdrew: Lost to follow-up | 7 | 1 |
| Withdrew: Withdrawal by subject | 6 | 1 |
| Withdrew: Protocol violation | 4 | 1 |
| Withdrew: Insufficient therapeutic effect | 1 | 0 |
An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| Subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Any AE | 175 | 82 |
| Any SAE | 20 | 6 |
| Subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Any AE | 38 | 7 |
| Any SAE | 0 | 0 |
| Subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Any AE | 13 | 5 |
| Any SAE | 1 | 0 |
Musculoskeletal adverse events were classified as following SOCs (preferred terms): "injury, poisoning and procedural complications" (forearm fracture, joint injury, ligament sprain, muscle strain) "musculoskeletal and connective tissue disorders" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Forearm fracture | 0.3 (0.01 to 1.84) | 0 (0 to 2.43) |
| Joint injury | 0 (0 to 1.22) | 0.7 (0.02 to 3.66) |
| Ligament sprain | 0.3 (0.01 to 1.84) | 0.7 (0.02 to 3.66) |
| Muscle strain | 0 (0 to 1.22) | 0.7 (0.02 to 3.66) |
| Arthralgia | 3 (1.38 to 5.6) | 1.3 (0.16 to 4.73) |
| Joint swelling | 0 (0 to 1.22) | 0.7 (0.02 to 3.66) |
| Musculoskeletal pain | 1 (0.21 to 2.88) | 0 (0 to 2.43) |
| Myalgia | 0.3 (0.01 to 1.84) | 0 (0 to 2.43) |
"N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| Beats per minute (bpm) | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 300, 150) | 93.4 ± 19.1 | 90.4 ± 16.9 |
| Change at Day 1 ((N= 294, 148) | 2.8 ± 9.7 | 0.3 ± 6.9 |
| Day 3: Pre-dose (N= 293, 146) | 84.3 ± 17.2 | 82.6 ± 16.2 |
| Change at Day 3 (N= 290, 146) | 1 ± 8.9 | -0.9 ± 7.1 |
The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 299, 150) | 136.8294 ± 18.3554 | 140.5933 ± 20.5113 |
| Change at Day 1 ( N= 292, 148) | 0.7123 ± 8.2587 | -0.0203 ± 8.5631 |
| Day 3: Pre-dose (N= 293, 146) | 139.4915 ± 17.3258 | 139.5685 ± 20.8174 |
| Change at Day 3 (N= 289, 146) | 1.5813 ± 9.2143 | 1.5616 ± 9.9322 |
The RR interval refers to the respective time interval in the Electrocardiogram. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 300, 150) | 670.7567 ± 142.6153 | 689.3067 ± 145.5957 |
| Change at Day 1 (N= 294, 148) | -20.6429 ± 74.3401 | -3.4797 ± 56.9955 |
| Day 3: Pre-dose (N= 293, 146) | 740.4778 ± 149.0964 | 754.6027 ± 150.1203 |
| Change at Day 3 (N= 290, 146) | -9.2862 ± 77.7582 | 10.5137 ± 67.1124 |
The QRS interval represents the time it takes for ventricular depolarization to occur. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 300, 150) | 89.0333 ± 7.8279 | 88.8067 ± 7.9264 |
| Change at Day 1 (N= 294, 148) | 0.119 ± 4.3799 | 1.223 ± 4.2568 |
| Day 3: Pre-dose (N= 293, 146) | 89.2423 ± 8.0196 | 89.3904 ± 7.8198 |
| Change at Day 3 (N= 289, 146) | 0.2768 ± 4.123 | 0.2877 ± 3.1687 |
The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 298, 150) | 341.1812 ± 33.9858 | 344.2333 ± 33.5494 |
| Change at Day 1 (N= 290, 148) | 2.5828 ± 15.213 | 1.1149 ± 11.5744 |
| Day 3: Pre-dose (N= 292, 146) | 358.3082 ± 34.0504 | 356.5822 ± 35.6653 |
| Change at Day 3 (N= 287, 146) | 6.0906 ± 16.1875 | 3.1644 ± 11.9586 |
QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 298, 150) | 419.5872 ± 19.3278 | 417.34 ± 18.5718 |
| Change at Day 1 (N= 290, 148) | 9.731 ± 14.2961 | 2.2905 ± 14.2544 |
| Day 3: Pre-dose (N= 292, 146) | 419.2055 ± 16.6815 | 412.7945 ± 17.0075 |
| Change at Day 3 (N= 287, 146) | 9.2509 ± 16.8132 | 1 ± 12.5346 |
QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively.
| milliseconds | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day 1: Pre-dose (N= 298, 150) | 391.1846 ± 19.1574 | 390.9467 ± 18.4339 |
| Change at Day 1 (N= 290, 148) | 7.0724 ± 11.3219 | 1.9122 ± 11.3058 |
| Day 3: Pre-dose (N= 292, 146) | 397.3767 ± 17.2179 | 392.6918 ± 18.8144 |
| Change at Day 3 (N= 287, 146) | 8.115 ± 13.5805 | 1.774 ± 9.3328 |
A significant QTc prolongation was considered when the QTc value was more than (\>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day1: Pre-dose QTcCalcFridericia>ULN (N= 300, 150) | 0.7 ± 19.1574 | 1.3 ± 18.4339 |
| Day1: Post-dose QTcCalcFridericia>ULN (N= 297,148) | 3 ± 11.3219 | 2 ± 11.3058 |
| Day1: Post-dose >30 ms from pre-dose (N= 297,148) | 2 ± 17.2179 | 0 ± 18.8144 |
| Day1: Post-dose >60 ms from pre-dose (N= 297,148) | 0.3 ± 13.5805 | 0 ± 9.3328 |
| Day3: Pre-dose QTcCalcFridericia>ULN (N= 293, 146) | 1.4 | 1.4 |
| Day3: Post-dose QTcCalcFridericia>ULN (N= 291,148) | 9.6 | 1.4 |
| Day3: Post-dose >30 ms from pre-dose (N= 291,148) | 17.9 | 3.4 |
| Day3: Post-dose >60 ms from pre-dose (N= 291,148) | 1.7 | 0.7 |
A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. "N" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Day1: Pre-dose QTc Calc Bazett > ULN (N= 300, 150) | 7.7 | 2.7 |
| Day1: Post-dose QTc Calc Bazett > ULN (N= 297,148) | 16.2 | 4.1 |
| Day1: Post-dose >30 ms from pre-dose (N= 297,148) | 5.4 | 0 |
| Day1: Post-dose >60 ms from pre-dose (N= 297,148) | 0 | 0 |
| Day3: Pre-dose QTc Calc Bazett > ULN (N= 293, 146) | 3.8 | 1.4 |
| Day3: Post-dose QTc Calc Bazett > ULN (N= 291,148) | 15.5 | 3.4 |
| Day3: Post-dose >30 ms from pre-dose (N= 291,148) | 9.6 | 2 |
| Day3: Post-dose >60 ms from pre-dose (N= 291,148) | 0.7 | 0.7 |
Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Clinical Cure | 86.2 | 95.3 |
| Clinical Failure | 5.7 | 2 |
| Indeterminate | 8.1 | 2.7 |
Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate. 'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; índeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Presumed Persistence | 6.8 | 2.2 |
| Presumed Eradication | 84.7 | 94.9 |
| Indeterminate | 8.4 | 2.9 |
Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Clinical Cure | 86.2 | 95.3 |
| Clinical Failure | 5.7 | 2 |
| Indeterminate | 8.1 | 2.7 |
Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy. 'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Clinical Improvement | 94.3 | 98 |
| Clinical Failure | 1 | 0.7 |
| Indeterminate | 4.7 | 1.4 |
Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Presumed Persistence | 1.2 | 0.7 |
| Presumed Eradication | 95.6 | 97.8 |
| Indeterminate | 3.2 | 1.5 |
Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Resolution | 92.2 | 98 |
| Clinical Failure | 4.6 | 0.7 |
| Indeterminate | 3.2 | 1.4 |
Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.
| Percentage of subjects | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Presumed Persistence | 5.5 | 0.7 |
| Presumed Eradication | 91.1 | 97.8 |
| Indeterminate | 3.4 | 1.5 |
Collected over All AEs and SAE were recorded from treatment start to test of cure visit; musculoskeletal AEs were recorded up to 1 year post-end of treatment (EOT) visit; subjects with musculoskeletal AEs 1 year after EOT were followed up to 5 years or until resolution.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxifloxacin (Avelox, BAY12-8039) | — | 20/301 (6.6%) | 127/301 (42.2%) |
| Comparator Ertapenem | — | 6/150 (4%) | 63/150 (42%) |
| Event | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Mechanical ileusGastrointestinal disorders | 3/301 | 2/150 |
| Abdominal abscessInfections and infestations | 3/301 | 0/150 |
| PhimosisCongenital, familial and genetic disorders | 0/301 | 1/150 |
| CellulitisInfections and infestations | 0/301 | 1/150 |
| Facial bones fractureInjury, poisoning and procedural complications | 0/301 | 1/150 |
| Generalised tonic-clonic seizureNervous system disorders | 0/301 | 1/150 |
| Idiopathic generalised epilepsyNervous system disorders | 0/301 | 1/150 |
| Intestinal obstructionGastrointestinal disorders | 2/301 | 0/150 |
| Functional gastrointestinal disorderGastrointestinal disorders | 2/301 | 0/150 |
| AnaemiaBlood and lymphatic system disorders | 1/301 | 0/150 |
| Event | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem |
|---|---|---|
| Incision site painInjury, poisoning and procedural complications | 26/301 | 14/150 |
| Electrocardiogram QT prolongedInvestigations | 28/301 | 4/150 |
| VomitingGastrointestinal disorders | 20/301 | 12/150 |
| Procedural painInjury, poisoning and procedural complications | 16/301 | 10/150 |
| Wound infectionInfections and infestations | 13/301 | 6/150 |
| DiarrhoeaGastrointestinal disorders | 11/301 | 1/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/301 | 2/150 |
| PyrexiaGeneral disorders | 6/301 | 4/150 |
| Procedural vomitingInjury, poisoning and procedural complications | 0/301 | 4/150 |
| Abdominal painGastrointestinal disorders | 8/301 | 3/150 |
| Age, Continuous(years) | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem | Total |
|---|---|---|---|
| Mean | 12.05 ± 3.66 | 12.046 ± 3.495 | 12.049 ± 3.602 |
| Age, Customized(Subjects) | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem | Total |
|---|---|---|---|
| 12 - < 18 years | 190 | 94 | 284 |
| 6 - < 12 years | 100 | 52 | 152 |
| 2 - < 6 years | 14 | 7 | 21 |
| 3 months - < 2 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Moxifloxacin (Avelox, BAY12-8039) | Comparator Ertapenem | Total |
|---|---|---|---|
| Female | 124 | 53 | 177 |
| Male | 181 | 100 | 281 |
Ran from Jul 2010 to primary completion in Jan 2015, 54 months.
Results were first posted in Dec 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin